CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma

Although subtypes of pancreatic ductal adenocarcinoma (PDAC) were described, this malignancy is clinically still treated as a single disease. Here, we present patient-derived models representing the full spectrum of previously identified quasi-mesenchymal (QM-PDA), classical and exocrine-like PDAC s...

Descripción completa

Detalles Bibliográficos
Autores principales: Noll, Elisa M., Eisen, Christian, Stenzinger, Albrecht, Espinet, Elisa, Muckenhuber, Alexander, Klein, Corinna, Vogel, Vanessa, Klaus, Bernd, Nadler, Wiebke, Rösli, Christoph, Lutz, Christian, Kulke, Michael, Engelhardt, Jan, Zickgraf, Franziska M., Espinosa, Octavio, Schlesner, Matthias, Jiang, Xiaoqi, Kopp-Schneider, Annette, Neuhaus, Peter, Bahra, Marcus, Sinn, Bruno V., Eils, Roland, Giese, Nathalia A., Hackert, Thilo, Strobel, Oliver, Werner, Jens, Büchler, Markus W., Weichert, Wilko, Trumpp, Andreas, Sprick, Martin R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780258/
https://www.ncbi.nlm.nih.gov/pubmed/26855150
http://dx.doi.org/10.1038/nm.4038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4780258/
https://www.ncbi.nlm.nih.gov/pubmed/26855150
http://dx.doi.org/10.1038/nm.4038

Ejemplares similares